Canakinumab
- SubcutCanakinumabIlaris
Mechanism of Action
- A human monoclonal antibody that binds to IL-1β and inhibits its activity, resulting in reduced acute phase response.
Clinical Use
- Indications
- Cryopyrin-associated periodic syndromes (CAPS) in adults and children aged 2 years or older
- Systemic juvenile idiopathic arthritis in patients aged 2 years or older
- Adverse Effects
- Injection site reactions
- Infections
- Neutropaenia
- Abdominal pain